Bristol Myers Squibb (CELG-RI) Assets Average (2009 - 2026)

Bristol Myers Squibb (CELG-RI) posted quarterly Assets Average of $88.3 billion for Q1 2026, down 4.6% YoY from $92.5 billion in Q1 2025, and down 5.57% sequentially from $93.5 billion in Q4 2025.

Bristol Myers Squibb (CELG-RI) Assets Average (2009 - 2026) Analysis & Trends

Bristol Myers Squibb has disclosed Assets Average across 17 years of filings, most recently posting $88.3 billion for Q1 2026.

  • In Q1 2026, Assets Average fell 4.6% year-over-year to $88.3 billion; the TTM figure through Mar 2026 stood at $88.3 billion (down 4.6% YoY), while the FY2025 annual figure was $91.3 billion, down 2.73% from the prior year.
  • Assets Average retreated to $88.3 billion in Q1 2026, from $93.5 billion in the prior quarter.
  • Over the last five years, Assets Average for CELG-RI reached as high as $106.2 billion in Q1 2022 and fell as low as $88.3 billion in Q1 2026.
  • The 5-year median for Assets Average is $94.2 billion (2024), against an average of $95.6 billion.
  • Annual changes were most pronounced in 2022 — Assets Average decreased 11.44% — and 2024, when it climbed 3.15%.
  • A 5-year view of Assets Average shows it stood at $97.5 billion in 2022, then retreated by 4.41% to $93.2 billion in 2023, then fell by 0.08% to $93.1 billion in 2024, then grew by 0.35% to $93.5 billion in 2025, then decreased by 5.57% to $88.3 billion in 2026.
  • According to Business Quant data, Assets Average over the past three periods registered $88.3 billion, $93.5 billion, and $95.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Assets Avg. (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 114.53 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 200.05 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 135.21 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 114.04 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 132.78 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 91.55 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 57.65 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 208.08 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Bristol Myers Squibb 244.56 Mn -10.21 Bn 8.07 Bn 88.26 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 88.26 Bn
Dec 31, 2025 93.46 Bn
Sep 30, 2025 95.78 Bn
Jun 30, 2025 93.55 Bn
Mar 31, 2025 92.52 Bn
Dec 31, 2024 93.14 Bn
Sep 30, 2024 94.16 Bn
Jun 30, 2024 96.84 Bn
Mar 31, 2024 97.10 Bn
Dec 31, 2023 93.21 Bn
Sep 30, 2023 92.38 Bn
Jun 30, 2023 93.89 Bn
Mar 31, 2023 95.55 Bn
Dec 31, 2022 97.51 Bn
Sep 30, 2022 99.28 Bn
Jun 30, 2022 101.70 Bn
Mar 31, 2022 106.17 Bn
Dec 31, 2021 110.10 Bn
Sep 30, 2021 110.85 Bn
Jun 30, 2021 111.62 Bn